Investor Presentation January 2018 D i s c l a i m e r This - PowerPoint PPT Presentation

Investor Presentation January 2018

D i s c l a i m e r This confidential document and the information contained in this document (the “ Presentation ”) constitutes neither an offer for sale or subscription nor a solicitation of a purchase or subscription order for Cellnovo shares in any country. No offer of shares is made, or will be made in France, before obtaining a visa from the Autorité des Marchés Financiers (the “ AMF” ) on a prospectus comprising a registration statement ( document de base ) and securities note ( note d’opération ) that will be submitted to the AMF. In particular, this Presentation does not constitute an offer for sale of securities or any solicitation of a purchase or subscription order for securities in the United States or by U.S. persons (as such terms are defined in Regulation S under the U.S. Securities Act of 1933, as amended (t he “ Securities Act ”). Cellnovo shares may be only offered or sold in the United States pursuant to an effective registration statement under the Securities Act or under an exemption from the registration requirement of the Securities Act. Cellnovo shares have not been and will not be registered under the Securities Act, and Cellnovo has no intention of making any public offering of its shares in the United States. This Presentation does not constitute a prospectus within the meaning of Directive 2003/71/EC of the European Parliament and of the Council of November 4, 2003, as amended, in particular by Directive 2010/73/EC of the European Parliament and of the Council of November 24, 2010 (the “ Prospectus Directive ”). Its dissemination may be governed by specific regulations in certain countries. Persons in possession of this Presentatio n should therefore acquaint themselves and comply with any local restrictions. No action has been taken or will be taken for the purpose of enabling a public offering of securities requiring the publication by Cellnovo of a prospectus in a Member State other than France. Consequently, the Cellnovo shares may not and will not be offered in any Member State other than France, except in accordance with the exceptions set forth in Article 3.2 of the Prospectus Directive or in other cases not requiring publication by the Company of a prospectus pursuant to Article 3.2 of the Prospectus Directive or other applicable regulations in that Member State. Regarding the United Kingdom, this Presentation has not been approved by an authorised person in accordance with Section 21 of the Financial Services and Markets Act 2000 and therefore it is intended to be delivered solely and for information purposes only to persons who (i) are investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as currently in effect, hereinafter the “ Financial Promotion Order ”), (ii) are referred to at Article 49(2) (a) to (d) (“high net worth companies, unincorporated associations, etc.”) of the F inancial Promotion Order, (iii) are outside the United Kingdom, or (iv) are persons to whom an Presentation or incitement to engage in investment activities (within the meaning of section 21 of the Financial Services and Markets Act 2000) in the context of the issuance or disposal of securities may legally be extended, directly or indirectly (all such persons being collectively named “ Authorised Persons ”). This Presentation may not be used by any person who is not an Authorised Person. By accepting this Presentation and not immediately returning it, the recipient represents and warrants that they are a person who falls within the above description of persons entitled to receive the Presentation. Page 2

A M a n a g e m e n t Te a m W i t h A S u c c e s s f u l Tr a c k R e c o r d Dr. Sophie Baratte CEO 20 years of experience in Sales & Marketing functions in the medical technology sector, including Sorin Group   Served as CEO of CIT, General Manager for the In Vitro Diagnostics branch of Johnson & Johnson in France and as senior EMEA Sales & Marketing Director for Lifecell Engineer, Ph.D. in biotechnology, MBA John Brooks Chairman Served as CEO and Founder of Insulet, and as CEO of Joslin Diabetes Center   Over 30 years of experience in the medical device industry in diabetes Javaid Masoud CTO  Served at Medtronic and at Sorin Group in Senior director roles for wireless technologies, embedded firmware development for implantable cardiac defibrillators, wireless communication protocol, embedded firmware for implantable devices, and software for external instruments Dr. Julian Shapley CSO, Founder  NASA experience  Founded Cellnovo in 2008 Ph.D. in micro-fluidics at Cardiff University Erwan Martin CFO  20 years of experience in finance and biotechnologies  Former CFO of Genomic Vision, co-founded Cytomics Pharmaceuticals, served as project manager at Syndex MBA at Warwick Business School Page 3

C e l l n o v o i n a N u t s h e l l The first connected, all-in-one Diabetes Management System • Cellnovo develops and commercialises a disruptive insulin micro-pump • A $2.5Bn market: Growing and well-reimbursed Focused on Type 1 diabetes with a potential for larger Type 2 market • Addressing clear market needs The only real-time data device, for better patient outcomes • Unique accuracy and safety features • A clearly defined global strategy supported by strategic partners - Roche: Contract for Blood Glucose Measurement - Flex: Manufacturing partner - Air Liquide: Major distribution partner • Road map towards Artificial Pancreas and smartphone • IPO on Euronext Paris in July 2015 • €20m loan agreement with the EIB – July 2017 • 1. North America+ Main European countries, Medtronic's, Investor Conference, June 2014 €17.5m capital raise from healthcare investors – July 2017 Page 4

Ty p e 1 D i a b e t e s : A l a r g e m a r k e t , w e l c o m i n g i n n o v a t i o n Pumps are providing short and long-term benefits to patients, despite low penetration T1 Patient Market * MDI Tubed Pump Micro-Pump US % Patient Use 70% 26% 4% EU % Patient Use 85% 12% 3% $2 B $400 M Market Size <5% 40% Growth Rate Market Players * Source: Company estimates Page 5

C e l l n o v o : A G a m e C h a n g e r f o r I n s u l i n P u m p Te c h n o l o g y Intuitive operation, wireless connectivity, real-time tracking, and Bluetooth and Android-enabled = All industry firsts Disposables Durables Insulin Cartridge Online Wireless Mobile Handset • • The insulin reservoir Real-time data • • Pumping mechanism Automated capture of data • Occlusion sensor and transmission • Analytics and trends • Stakeholders access • Pump microprocessors and • memory High resolution, full-colour touchscreen • • Rechargeable battery GSM Modem • • Accelerometer Micro SD port • • Precision reservoir sensor Apps-friendly • Roche BG Meter integrated • Bolus calculator The perfect combination between a new generation of micro-pump and a mobile handset to allow the best accuracy and a 24/7 health remote monitoring Page 6

C e l l n o v o , a B r e a k t h r o u g h i n I n s u l i n D e l i v e r y, f o r a l l S t a k e h o l d e r s The only e-connected, accurate, wearable insulin micro-pump Freedom and peace of mind • Real time information to drive better patient outcomes • Unrivalled accuracy and safety of drug delivery in micro-pumps Driving Savings • Ideal pump for lifestyle, wearability, comfort • Informing payers of compliance to • High demand from patients treatment • E- connected for family’s peace of • Lower pricing compared to other mind micro-pumps • Interoperability with connected devices (CGM, BGM, activity Cost Effective Patients’ support trackers, e-watches) • Effective patients’ communication and trouble shooting, based on real time back-end data Page 7

C e l l n o v o , t h e F i r s t C o n n e c t e d M i c r o - P u m p A l l o w i n g M a x i m u m I n t e r o p e r a b i l i t y i n t h e D i a b e t e s E c o s y s t e m BLOOD GLUCOSE ALGORITHMS METERS PATIENT WEARABLES, CONTINUOUS HEALTH GLUCOSE Dexcom MONITORS MONITORS FOOD LIBRARIES Cellnovo Dataflow Other Dataflows Page 8

Agenda 1. A unique technology 2. A company well-placed on COGS 3. An aggressive commercial strategy 4. The next breakthrough: The Artificial Pancreas 5. Financials

C e l l n o v o B e n e f i t s C o m p a r e s P o s i t i v e l y t o t h e o t h e r M i c r o - p u m p s E-health in real time Detachable Better outcomes For additional and peace of mind comfort Higher accuracy of delivery Enhanced safety High quality of A key feature for all treatment Touchscreen colour Disposable plastics Handset Intuitive usage Better COGS Bluetooth and and eco-friendly device Android-enabled Page 10